SEMAGLUTIDE improves hepatic steatosis, disease activity and promotes the resolution of metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, while also promoting weight loss and enhancing metabolic health. These benefits from once-weekly subcutaneous semaglutide were demonstrated in the multicentre, placebo-controlled ESSENCE trial. Clinical Outcomes of Semaglutide in Patients with MASHThe phase 3 ESSENCE trial enrolled 800 patients with biopsy-confirmed MASH and fibrosis stage F2–F3 and demonstrated that semaglutide 2.4 mg/week produced significant histological and metabolic benefits over 72 weeks. Among the 534 patients receiving semaglutide, 62.9% achieved MASH resolution without worsening fibrosis compared with 34.3% in the placebo group. Additionally, evidence on semaglutide’s impact on muscle mass and sarcopenia, as well as its effectiveness in individuals with lower BMI or without significant metabolic dysfunction, is limited and warrants further investigation.